Neola Medical (NEOLA.ST) Stock Analysis & AI Equity Report
Neola Medical (NEOLA.ST) overview
Neola Medical (NEOLA.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Neola Medical reported revenue of SEK 0m and operating profit of SEK -11.1m; the year-end share price was 1.06 SEK and market capitalisation was SEK 81.2m. Neola Medical is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Neola Medical's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About Neola Medical
Neola Medical AB (publ) develops Neola, a medical device for continuous, non-invasive lung monitoring in preterm newborns. The company focuses on neonatal intensive care and is working toward market authorization and commercial launch. Its business is built around device development, regulatory approval, and future sales of monitoring systems and disposable probes.
Generate the Neola Medical report
Neola Medical is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Neola Medical and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.